
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cryosite Limited is a diagnostics & research business based in Australia. Cryosite shares (CTE) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Cryosite has a trailing 12-month revenue of around $9 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, Cryosite 's share price has had significant positive movement.
Its last market close was $0.25, which is 78.80% up on its pre-crash value of $0.053 and 400.00% up on the lowest point reached during the March crash when the shares fell as low as $0.05.
If you had bought $1,000 worth of Cryosite shares at the start of February 2020, those shares would have been worth $1,358.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $4,716.98.
52-week range | $0.047 - $0.3 |
---|---|
50-day moving average | $0.2133 |
200-day moving average | $0.152 |
Target price | N/A |
PE ratio | 7.9208 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.03 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.25 on 2020-10-22
1 week (2021-01-11) | -39.02% |
---|---|
1 month (2020-12-18) | -28.57% |
3 months (2020-10-16) | 4.17% |
6 months (2020-07-17) | 78.57% |
1 year (2020-01-17) | 354.55% |
---|---|
2 years (2019-01-14) | N/A |
3 years (2018-01-17) | 127.27% |
5 years (2016-01-14) | N/A |
Valuing Cryosite stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cryosite 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cryosite 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Cryosite shares trade at around 8x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Cryosite 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $952,651 (£542,150).
The EBITDA is a measure of a Cryosite 's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $9 million |
---|---|
Operating margin TTM | 8.5% |
Gross profit TTM | $4 million |
Return on assets TTM | 2.04% |
Return on equity TTM | -1515.36% |
Profit margin | 16.5% |
Book value | -0.037 |
Market capitalisation | $11.7 million |
TTM: trailing 12 months
We're not expecting Cryosite to pay a dividend over the next 12 months.
Cryosite 's shares were split on 29 April 2004.
Over the last 12 months, Cryosite 's shares have ranged in value from as little as $0.047 up to $0.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cryosite 's is -0.1927. This would suggest that Cryosite 's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cryosite has bucked the trend.
Cryosite Limited engages in the supply chain logistics and management of pharmaceutical products used in clinical trials, and biological materials in Australia. It operates in two segments, Clinical Trials & Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials & Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was founded in 1999 and is based in South Granville, Australia.
From the best RC plane for beginners to the top model for aerial photography, these are the six best RC planes in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.